Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer

Trends Cancer. 2024 Dec;10(12):1093-1094. doi: 10.1016/j.trecan.2024.10.006. Epub 2024 Oct 24.

Abstract

Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.

Keywords: MSI; colorectal cancer; dMMR; immune checkpoint inhibition; neoadjuvant therapy.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / immunology
  • Colorectal Neoplasms* / pathology
  • Colorectal Neoplasms* / therapy
  • DNA Mismatch Repair*
  • Humans
  • Immune Checkpoint Inhibitors* / pharmacology
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Immunotherapy / methods
  • Microsatellite Instability*
  • Neoadjuvant Therapy* / methods

Substances

  • Immune Checkpoint Inhibitors